These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 29193819

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, GRIPHON Investigators.
    N Engl J Med; 2015 Dec 24; 373(26):2522-33. PubMed ID: 26699168
    [Abstract] [Full Text] [Related]

  • 23. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis.
    Watson HR, Robb R, Belcher G, Belch JJ.
    J Rheumatol; 1999 Aug 24; 26(8):1734-7. PubMed ID: 10451070
    [Abstract] [Full Text] [Related]

  • 24. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, Bowcock SM, Kirby JD.
    Br J Dermatol; 1987 Aug 24; 117(2):237-41. PubMed ID: 3307894
    [Abstract] [Full Text] [Related]

  • 25. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.
    Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, Murphy E, Steinberg M.
    Ann Rheum Dis; 1995 Mar 24; 54(3):197-200. PubMed ID: 7538285
    [Abstract] [Full Text] [Related]

  • 26. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O.
    J Dermatol; 2016 Jan 24; 43(1):56-62. PubMed ID: 26173902
    [Abstract] [Full Text] [Related]

  • 27. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
    Hoch M, Darpo B, Remenova T, Stoltz R, Zhou M, Kaufmann P, Bruderer S, Dingemanse J.
    Drug Des Devel Ther; 2015 Jan 24; 9():175-85. PubMed ID: 25552906
    [Abstract] [Full Text] [Related]

  • 28. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.
    Am J Cardiovasc Drugs; 2018 Feb 24; 18(1):37-47. PubMed ID: 29307087
    [Abstract] [Full Text] [Related]

  • 29. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A.
    Cochrane Database Syst Rev; 2000 Feb 24; 1998(2):CD000953. PubMed ID: 10796395
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.
    Negrini S, Spanò F, Penza E, Rollando D, Indiveri F, Filaci G, Puppo F.
    Clin Exp Med; 2016 Aug 24; 16(3):407-12. PubMed ID: 26088182
    [Abstract] [Full Text] [Related]

  • 32. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W.
    Ann Intern Med; 1994 Feb 01; 120(3):199-206. PubMed ID: 7506013
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).
    Kim NH, Channick R, Delcroix M, Madani M, Pepke-Zaba J, Borissoff JI, Easton V, Gesang S, Richard D, Ghofrani HA.
    Eur Respir J; 2024 Oct 01; 64(4):. PubMed ID: 39326918
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.
    Muir AH, Robb R, McLaren M, Daly F, Belch JJ.
    Vasc Med; 2002 Oct 01; 7(4):265-7. PubMed ID: 12710841
    [Abstract] [Full Text] [Related]

  • 40. Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients　- A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study.
    Tanabe N, Fukuda K, Matsubara H, Nakanishi N, Tahara N, Ikeda S, Kishi T, Satoh T, Hirata KI, Inoue T, Kimura H, Okano Y, Okazaki O, Sata M, Tsujino I, Ueno S, Yamada N, Yao A, Kuriyama T.
    Circ J; 2020 Sep 25; 84(10):1866-1874. PubMed ID: 32879152
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.